Therapeutic Efficacy And Clinical Outcomes Of Ursodeoxycholic Acid In Gallstone Disease And Metabolic Liver Disorders: A Narrative Review
Bilah Samping Artikel
Isi Artikel Utama
Abstrak
Ursodeoxycholic acid (UDCA) is a hydrophilic bile acid used in selected hepatobiliary disorders and cholesterol gallstone disease, with increasing interest in its cytoprotective, anti-inflammatory, and metabolic effects in metabolic dysfunction-associated steatotic liver disease (MASLD). This narrative review aimed to evaluate the therapeutic efficacy, clinical outcomes, safety, and limitations of UDCA in gallstone disease and metabolic liver disorders. Literature was identified from PubMed, ScienceDirect, and Google Scholar, prioritizing studies published between 2021 and 2026, while earlier landmark randomized trials were included when essential to assess dose, histological outcomes, or long-term efficacy. The evidence was analyzed qualitatively and synthesized thematically according to pharmacological mechanisms, gallstone prevention and dissolution, biochemical and histological liver outcomes, safety, dosing, and the potential dual role of UDCA in coexisting MASLD and gallstone disease. UDCA showed the greatest benefit in selected patients with small, radiolucent, cholesterol-rich, newly formed gallstones or biliary sludge and may reduce post-bariatric gallstone formation, biliary symptoms, hospital utilization, and the need for intervention. In metabolic liver disorders, UDCA consistently improved biochemical markers, particularly ALT, AST, and GGT, but these effects did not consistently translate into histological improvement or fibrosis regression. These findings indicate that UDCA has stronger evidence as a selective therapy for cholesterol gallstone disease than as a disease-modifying treatment for MASLD. Its role in metabolic liver disorders is best considered adjunctive, while direct evidence of simultaneous hepatic and biliary benefit remains limited.
Rincian Artikel
Artikel ini berlisensiCreative Commons Attribution-ShareAlike 4.0 International License.
Referensi
Al-Huniti, M., Alsardi, Y., Odeh, A., Bdour, B., Hassanat, R., Aloun, A., Sha’ban, B. W., & Nseirat, S. M. (2023). Ursodeoxycholic Acid Prophylaxis and the Reduction of Gallstone Formation After Bariatric Surgery: An Updated Meta-Analysis of Randomized Controlled Trials. Cureus. https://doi.org/10.7759/cureus.50649https://doi.org/10.7759/cureus.50649
Alrubaiaan, A., Altunaib, F., AlMutairi, S. A., AlFadhly, N., & AlKandari, A. F. (2026). Efficacy of prophylactic ursodeoxycholic acid in preventing gallstone formation after metabolic bariatric surgery: An updated systematic review and meta-analysis of randomized controlled trials. BMC Surgery. https://doi.org/10.1186/s12893-026-03983-0
Amin, M., Amin, F., Ather, A., & Ahmad, S. (2025). Comparison of vitamin E and ursodeoxycholic acid in non-alcoholic steatohepatitis (NASH). Pakistan Journal of Intensive Care Medicine, 5(02), 128. https://doi.org/10.54112/pjicm.v5i02.128https://doi.org/10.54112/pjicm.v5i02.128
Armandi, A., & Bugianesi, E. (2024). Dietary and pharmacological treatment in patients with metabolic-dysfunction associated steatotic liver disease. European Journal of Internal Medicine, 122, 20–27. https://doi.org/10.1016/j.ejim.2024.01.005
Buyuker, F., Sermet, M., Ozsoy, M. S., Tosun, S., Ekinci, Ö., Baysal, H., & Alimoglu, O. (2025). The effect of ursodeoxycholic acid in dissolving gallstones formed after laparoscopic sleeve gastrectomy: Retrospective cohort study. Langenbeck’s Archives of Surgery, 410(1), 91. https://doi.org/10.1007/s00423-025-03656-1
Cao, Y., Xiang, L., Qi, F., Zhang, Y., Chen, Y., & Zhou, X. (2022). Accuracy of controlled attenuation parameter (CAP) and liver stiffness measurement (LSM) for assessing steatosis and fibrosis in non-alcoholic fatty liver disease: A systematic review and meta-analysis. eClinicalMedicine, 51, 101547. https://doi.org/10.1016/j.eclinm.2022.101547
Chang, Y., Cho, Y. K., Kim, Y. S., Kim, S.-E., Cheon, G. J., Kim, J. H., Yang, H., Kim, W., Ahn, S. B., Yoon, E. L., Cheong, J. Y., Lee, J.-W., Kim, M. Y., Kim, H. J., Lee, S. H., Cho, E. Y., Choi, N. R., Lee, H. W., Kim, K. M., … Jang, J. Y. (2026). Standard-Dose Ursodeoxycholic Acid Improves Biochemical Liver Function and Fibrosis in Chronic Liver Disease: Multicenter, Randomized, Double-Blind, Placebo-Controlled Trial. Journal of Korean Medical Science, 41(19), e89. https://doi.org/10.3346/jkms.2026.41.e89
Demirpolat, M. T., Celikkaya, M. O., Ertekin, S. C., Basak, F., & Sisik, A. (2025). Efficacy of ursodeoxycholic acid in reducing the necessity of cholecystectomy due to pre-existing and subsequently formed gallstones in patients who underwent laparoscopic sleeve gastrectomy. BMC Surgery, 25(1), 30. https://doi.org/10.1186/s12893-025-02767-2
Dong, X., Sun, W., Xu, H., Xie, Y., He, J., Liu, X., Liu, X., Ali, A., Chen, M., Zhang, L., Wu, L., & Shao, K. (2026). Ursodeoxycholic acid alleviates high-fat diet-induced liver injury by modulating gut microbiota-mediated bile acid metabolism: An integrated microbiota-metabolomics analysis. Frontiers in Nutrition, 13, 1714100. https://doi.org/10.3389/fnut.2026.1714100
European Association for the Study of the Liver (EASL), European Association for the Study of Diabetes (EASD), & European Association for the Study of Obesity (EASO). (2024). EASL-EASD-EASO Clinical Practice Guidelines on the Management of Metabolic Dysfunction-Associated Steatotic Liver Disease (MASLD). Obesity Facts, 17(4), 374–444. https://doi.org/10.1159/000539371
Fersahoğlu, M., Çakmak, A., Çiyiltepe, H., Esen Bulut, N., Fersahoğlu, A., Karip, A., Ergin, A., Bilgili, A., & Memişoğlu, K. (2022). The effect of different doses of ursodeoxycholic acid on gallstone formation after sleeve gastrectomy. Journal of Istanbul Faculty of Medicine / İstanbul Tıp Fakültesi Dergisi, 85(1), 29–34. https://doi.org/10.26650/IUITFD.948141https://doi.org/10.26650/IUITFD.948141
Fujita, N., Yasuda, I., Endo, I., Isayama, H., Iwashita, T., Ueki, T., Uemura, K., Umezawa, A., Katanuma, A., Katayose, Y., Suzuki, Y., Shoda, J., Tsuyuguchi, T., Wakai, T., Inui, K., Unno, M., Takeyama, Y., Itoi, T., Koike, K., & Mochida, S. (2023). Evidence-based clinical practice guidelines for cholelithiasis 2021. Journal of Gastroenterology, 58(9), 801–833. https://doi.org/10.1007/s00535-023-02014-6
Hall, L., Halle-Smith, J., Evans, R., Toogood, G., Wiggins, T., Markar, S. R., Kapoulas, S., Super, P., Tucker, O., & McKay, S. C. (2023). Ursodeoxycholic acid in the management of symptomatic gallstone disease: Systematic review and clinician survey. BJS Open, 7(2), zrac152. https://doi.org/10.1093/bjsopen/zrac152
Hossain, I., Brodie, J., O’Brien, E., Tedman-Aucoin, K., Lawlor, D., Murphy, R., Twells, L., Pace, D., Evans, B., & Ellsmere, J. (2023). Ursodeoxycholic acid for prevention of gallstone disease after laparoscopic sleeve gastrectomy: An Atlantic Canada perspective. Surgical Endoscopy, 37(7), 5236–5240. https://doi.org/10.1007/s00464-023-10015-y
Khurmatullina, A. R., Andreev, D. N., Maev, I. V., Zaborovsky, A. V., Kucheryavyy, Y. A., Beliy, P. A., & Sokolov, P. S. (2026). Efficacy of ursodeoxycholic acid in metabolic dysfunction-associated steatotic liver disease: An umbrella review of meta-analyses on liver enzymes. Frontiers in Medicine, 13, 1771830. https://doi.org/10.3389/fmed.2026.1771830
Lee, S. Y., Jang, S. I., Cho, J. H., Do, M. Y., Lee, S. Y., Choi, A., Lee, H. S., Yang, J., & Lee, D. K. (2024). Gallstone Dissolution Effects of Combination Therapy with n-3 Polyunsaturated Fatty Acids and Ursodeoxycholic Acid: A Randomized, Prospective, Preliminary Clinical Trial. Gut and Liver, 18(6), 1069–1079. https://doi.org/10.5009/gnl230494
Leuschner, U. F. H., Lindenthal, B., Herrmann, G., Arnold, J. C., Rössle, M., Cordes, H., Zeuzem, S., Hein, J., & Berg, T. (2010). High‐dose ursodeoxycholic acid therapy for nonalcoholic steatohepatitis: A double‐blind, randomized, placebo‐controlled trial†. Hepatology, 52(2), 472–479. https://doi.org/10.1002/hep.23727
Li, H., Wang, Q., Chen, P., Zhou, C., Zhang, X., & Chen, L. (2021). Ursodeoxycholic Acid Treatment Restores Gut Microbiota and Alleviates Liver Inflammation in Non-Alcoholic Steatohepatitic Mouse Model. Frontiers in Pharmacology, 12, 788558. https://doi.org/10.3389/fphar.2021.788558
Lindor, K. D., Kowdley, K. V., Heathcote, J. E., Harrison, E. M., Jorgensen, R., Angulo, P., Lymp, J. F., Burgart, L., & Colin, P. (2004). Ursodeoxycholic acid for treatment of nonalcoholic steatohepatitis: Results of a randomized trial. Hepatology, 39(3), 770–778. https://doi.org/10.1002/hep.20092
Mali, D., Gupta, S., A.K.Kaundal, Sharma, B., & Bodh, V. (2025). Prevalence and Severity of Metabolic Dysfunction-Associated Steatotic Liver Disease Among Patients with Gallstone Disease: A Prospective Hospital-Based Study. International Academic Research Journal of Surgery, 05(01), 1–6. https://doi.org/10.47310/iarjs.2025.v05i01.021
Nadinskaia, M., Maevskaya, M., Ivashkin, V., Kodzoeva, K., Pirogova, I., Chesnokov, E., Nersesov, A., Kaibullayeva, J., Konysbekova, A., Raissova, A., Khamrabaeva, F., & Zueva, E. (2021). Ursodeoxycholic acid as a means of preventing atherosclerosis, steatosis and liver fibrosis in patients with nonalcoholic fatty liver disease. World Journal of Gastroenterology, 27(10), 959–975. https://doi.org/10.3748/wjg.v27.i10.959
Patel, V. S., Mahmood, S. F., Bhatt, K. H., Khemkar, R. M., Jariwala, D. R., Harris, B., George, M. M., Kurudamannil, R. A., Anyagwa, O. E., Tak, R. S., & Kassem, M. (2024). Ursodeoxycholic Acid’s Effectiveness in the Management of Nonalcoholic Fatty Liver Disease: A Systematic Review and Meta-analysis. Euroasian Journal of Hepato-Gastroenterology, 14(1), 92–98. https://doi.org/10.5005/jp-journals-10018-1434
Stan, S. I., Biciușcă, V., Clenciu, D., Mitrea, A., Boldeanu, M.-V., Durand, P., & Dănoiu, S. (2024). The therapeutic mechanisms and beneficial effects of ursodeoxycholic acid in the treatment of nonalcoholic fatty liver disease: A systematic review. Medicine and Pharmacy Reports, 97(1), 12–25. https://doi.org/10.15386/mpr-2629https://doi.org/10.15386/mpr-2629
Woreta, T. A., Van Natta, M. L., Lazo, M., Krishnan, A., Neuschwander-Tetri, B. A., Loomba, R., Mae Diehl, A., Abdelmalek, M. F., Chalasani, N., Gawrieh, S., Dasarathy, S., Vuppalanchi, R., Siddiqui, M. S., Kowdley, K. V., McCullough, A., Terrault, N. A., Behling, C., Kleiner, D. E., Fishbein, M., … for the NASH Clinical Research Network. (2022). Validation of the accuracy of the FASTTM score for detecting patients with at-risk nonalcoholic steatohepatitis (NASH) in a North American cohort and comparison to other non-invasive algorithms. PLOS ONE, 17(4), e0266859. https://doi.org/10.1371/journal.pone.0266859
Zhang, Y., Zhang, J., Yu, D., Tu, F., Liu, J., Han, B., Li, B., Yuan, Y., Chen, C., & Zhou, M. (2025). Association between metabolic dysfunction associated steatotic liver disease and gallstones in the US population using propensity score matching. Scientific Reports, 15(1), 910. https://doi.org/10.1038/s41598-025-85218-5